amgen singapore manufacturing

What amgen singapore manufacturing does

Amgen Singapore Manufacturing is the Singapore operating arm of Amgen Inc. (NASDAQ: AMGN), an independent biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The Singapore entity comprises two co-located facilities at Tuas Biomedical Park: a Next-Generation Biomanufacturing plant opened in 2014 — Amgen's first manufacturing site in Asia — and a commercial chemical synthesis manufacturing facility opened in 2015 that produces active pharmaceutical ingredients for the global product portfolio. A 7,500-square-meter NextGen Workplace innovation hub, launched in 2018, supports both facilities. The site employs 350+ people spanning 17 nationalities and four generations, and operates an innovative Wastewater Treatment Plant that saves 26,000 m³ of water annually.

Amgen's commercial product portfolio spans four therapeutic areas — oncology and hematology (including the proprietary BiTE bispecific T-cell engager platform), cardiovascular disease (PCSK9 inhibition), inflammation (rheumatoid arthritis, psoriasis biologics), and bone health/osteoporosis (RANK ligand pathway antibodies). Underlying discovery is supported by the Generative Biology AI/ML platform for protein drug design and the deCODE Genetics multi-omics platform for human genetics-driven biomarker and target identification. Amgen holds a portfolio of 13 therapeutic modalities overall and reaches patients in 100+ countries.

Revenue mechanics flow through two Singapore entities: Amgen Singapore Manufacturing (production and operations) and Amgen Biotechnology Singapore Pte Ltd (commercial sales). Product distribution is sales-led and regulated — prescription biologics are sold through healthcare providers, hospitals, oncology centers, and specialty practices across Singapore and the broader Asia-Pacific region, supported by medical science liaisons and field sales teams. Pricing is regulated and not publicly disclosed. Partnerships with the Singapore Heart Foundation, Bone Health Alliance members, Singapore EDB, SkillsFuture, Workforce Singapore, IMDA, NSG BioLabs (Golden Ticket program extended through 2027), Science Center Singapore, NUS, and the Amgen Foundation's education platforms (Amgen Biotech Experience, Amgen Scholars, LabXchange, Khan Academy sponsorship) anchor the commercial and ecosystem strategy.

Name

amgen singapore manufacturing

Legal name

Amgen Biotechnology Singapore Pte Ltd

Website

https://amgen.com.sg

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

1–10 employees

Short description

Amgen Singapore Manufacturing is the Asia manufacturing and commercial arm of Amgen Inc., operating a Next-Generation Biomanufacturing plant and chemical synthesis facility at Tuas Biomedical Park to produce and sell biologic medicines across oncology, cardiovascular, inflammation, and bone health in Singapore and the broader Asia-Pacific region.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Biopharmaceutical manufacturing
• Biologic medicines
• Active pharmaceutical ingredients
• Oncology biologics
• Biomanufacturing facility

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Infrastructure, Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Biologic Medicines Sales: Amgen develops and commercializes biologic medicines (proteins made using living cells) for the treatment of serious illnesses including cancer, cardiovascular disease, osteoporosis, inflammatory diseases, and rare diseases. Revenue is generated through product sales across 100+ countries.
2. Active Pharmaceutical Ingredients (API) Manufacturing: Amgen Singapore's chemical synthesis manufacturing facility produces active pharmaceutical ingredients for commercial use, supporting Amgen's global product portfolio.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Amgen Singapore Manufacturing operates a Next-Generation Biomanufacturing facility and a commercial chemical synthesis manufacturing facility at Tuas Biomedical Park, producing biologic medicines and active pharmaceutical ingredients that support Amgen's global oncology, cardiovascular, inflammation, and bone health product portfolio. The Singapore site is Amgen's first manufacturing presence in Asia and the first Next-Generation Biologics facility in Asia, integrating multiple innovative manufacturing technologies in one plant at substantially lower capital cost, operating cost, and environmental footprint than traditional facilities.

Product overview

Amgen Singapore Manufacturing operates as a multi-product, award-winning biotechnology manufacturing and commercial operations entity in Singapore. Its core portfolio includes innovative biologics and biosimilars across four therapeutic areas: Oncology & Hematology (including colorectal cancer, leukemia, and multiple myeloma), Cardiovascular Disease (cholesterol/PCSK9 inhibitors), Inflammation (autoimmune biologics), and Bone Health/Osteoporosis (RANK ligand pathway therapies). Key technology platforms supporting these products include the BiTE (Bispecific T-cell Engager) platform for immuno-oncology, the Generative Biology platform using AI and ML for protein drug discovery, and the deCODE multi-omics platform for human genetic data analysis. In Singapore, Amgen operates its first Next-Generation Biologics manufacturing facility in Asia (2014), a commercial chemical synthesis facility (2015), and a NextGen Workplace innovation hub (2018) at Tuas Biomedical Park. Beyond therapeutics, Amgen supports science education through the Amgen Foundation programs including the Amgen Biotech Experience (ABE), Amgen Scholars, LabXchange, and Khan Academy biology content sponsorship. The Amgen Golden Ticket Award (in partnership with NSG BioLabs) supports biotech startup innovation in Singapore.

Differentiator

Problem solved

Functional benefit

Products and services

• Biologic medicines portfolio (oncology, cardiovascular, inflammation, bone health) Innovative biologic medicines and biosimilars manufactured in Singapore for the treatment of serious illnesses including cancer (colorectal, lung, prostate, breast, leukemia, multiple myeloma), cardiovascular disease (PCSK9 cholesterol inhibition), chronic inflammatory diseases (rheumatoid arthritis, psoriasis), and osteoporosis (RANK ligand pathway therapies). Distributed across Singapore and the broader Asia-Pacific region via healthcare provider engagement.
• BiTE (Bispecific T-cell Engager) Platform Proprietary bispecific immunotherapy platform that engages the body's immune system (T cells) against specific tumor-associated antigens. Includes original BiTE molecules requiring continuous IV infusion and half-life extended (HLE) BiTE molecules for less-frequent dosing, applicable across blood cancers and solid tumors.
• Generative Biology AI/ML Platform AI and machine learning-powered computational modeling platform that predicts protein structures and reduces drug discovery timelines for therapeutic protein design, increasing success rates in protein drug discovery and development.
• deCODE Multi-Omics Platform Genomics and multi-omics platform (genomics, transcriptomics, proteomics, metabolomics) through Amgen's Icelandic subsidiary deCODE, enabling biomarker identification, disease prediction and progression tracking, clinical trial optimization, and delivery of transformative therapies through human genetic data analysis.
• Active Pharmaceutical Ingredients (API) Manufacturing Commercial-scale chemical synthesis manufacturing producing active pharmaceutical ingredients at the Tuas Biomedical Park site to support Amgen's global product portfolio.

Quantifiable outcome

• 26,000 m³ of water saved annually through the Wastewater Treatment Plant, achieving 100% reduction in water consumption
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature5 records

Partnerships

17 partnerships are on record, tiered core and minor.

• NSG BioLabscoreStrategic or Co-development Partner · 17 July 2024Amgen partners with NSG BioLabs through the Amgen Golden Ticket Program, supporting innovative biotech startups in Singapore. The program awards startups mentorship from Amgen's scientific and business leaders and one-year free access to NSG BioLabs' co-working laboratories. The partnership was extended for another three years (through 2027) following the third annual competition in July 2024, where PairX Bio was awarded the Golden Ticket.
• Science Center SingaporecoreStrategic or Co-development Partner · 1 January 2017The Amgen Foundation launched the Amgen Biotech Experience in Singapore in 2017 in collaboration with the Science Center Singapore, providing local mainstream secondary teachers and students with professional development, research-grade equipment, and hands-on curriculum to transform biology education.
• National University of Singapore (NUS)coreStrategic or Co-development Partner · 1 January 2017The Amgen Scholars Program, in partnership with the National University of Singapore (NUS), offers undergraduates from around the world the chance to engage in cutting-edge research projects during the summer. Launched in 2017 and expanded in 2018, the program provides hands-on lab experience working alongside leading scientists.
• Singapore Heart FoundationcoreStrategic or Co-development PartnerAmgen collaborates with the Singapore Heart Foundation to enhance efforts in preventing cardiovascular disease among Singaporeans, supporting awareness and preventive disease management initiatives.
• The Good Life Medical CentreminorStrategic or Co-development PartnerAmgen partners with The Good Life Medical Centre as part of the Bone Health Alliance to promote awareness and preventive measures for bone health.
• Frontier HealthcareminorStrategic or Co-development PartnerAmgen partners with Frontier Healthcare to support bone health awareness and disease prevention initiatives.
• Singapore Economic Development Board (EDB)coreStrategic or Co-development PartnerAmgen partners with Singapore EDB to develop a highly skilled workforce for Singapore's biologics manufacturing sector, supporting industry development and talent pipeline initiatives.
• SkillsFuture Singapore (SSG)coreStrategic or Co-development PartnerAmgen partners with SkillsFuture Singapore to support the development of a future-ready talent pipeline for Singapore's biologics manufacturing sector through industry development programs.
• Workforce Singapore (WSG)coreStrategic or Co-development PartnerAmgen partners with Workforce Singapore to develop a highly skilled workforce for Singapore's biologics manufacturing sector through targeted industry development programs.
• Infocomm Media Development Authority (IMDA)coreTechnology or IntegrationAmgen partners with IMDA's Open Innovation Platform to integrate advanced technology into its manufacturing operations, utilizing Autonomous Guided Vehicles (AGVs) to enhance operational efficiencies and worker safety.
• Harvard UniversitycoreStrategic or Co-development PartnerLabXchange, funded by the Amgen Foundation, was developed at Harvard University as a free online platform for science learning providing personalized instruction, virtual lab experiences, and networking across the global scientific community.
• LabXchangecoreStrategic or Co-development PartnerLabXchange, funded by the Amgen Foundation and developed at Harvard University, provides a free online platform for science learning with digital content from leading science organizations, available in 14+ languages and covering multiple scientific disciplines.
• Khan AcademycoreStrategic or Co-development PartnerSince 2015, the Amgen Foundation has been the exclusive sponsor of Khan Academy's online biology resources, which include high school and college-level biology content spanning multiple subjects in 50+ languages.
• PairX BiominorStrategic or Co-development PartnerPairX Bio was awarded the 2024 Amgen Golden Ticket Award, receiving mentorship from Amgen's scientific and business leaders and one-year residency at NSG BioLabs. PairX Bio develops next-generation cancer-selective biologics based on tumor-selective cell surface variants.
• Albatroz TherapeuticsminorStrategic or Co-development PartnerAmgen Golden Ticket winner developing therapeutic antibodies to treat solid tumors. Following their award, Albatroz raised seed funding of US$3 million in early 2023.
• VerImmuneminorStrategic or Co-development PartnerAmgen Golden Ticket winner focused on redirecting pre-existing immune memory from past infections or childhood vaccines to target cancer. Raised US$3.1 million in 2023 and achieved successful FDA pre-IND meeting.
• Leading Academic InstitutionscoreStrategic or Co-development PartnerAmgen partners with leading academic institutions in Singapore to nurture a future-ready talent pipeline for the biotech sector, supporting industry development and workforce readiness programs.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Sanofi: Global biopharmaceutical company with biologics capabilities and Asia-Pacific manufacturing presence; comparable as a broad incumbent producing innovative biologic therapies for serious illnesses.
• AbbVie: Global biopharmaceutical company with leading biologic immunology and oncology assets; comparable as an innovative biologics manufacturer and commercial player in overlapping therapeutic areas.
• Bristol-Myers Squibb: Innovative biopharmaceutical company with a biologics-heavy oncology and immunology portfolio and global commercial manufacturing; comparable as a biologic producer across overlapping therapeutic categories.
• Novartis: Major biopharmaceutical company with biologics manufacturing and a long-standing Singapore presence; comparable as a large innovative-biologics producer in oncology and cardiovascular disease targeting Asia-Pacific.
• Roche: Global biopharmaceutical leader with deep biologics manufacturing footprint and commercial operations in Singapore; broader incumbent that manufactures and sells its own biologics portfolio across overlapping therapeutic areas.

Direct peers

• Catalent: US-headquartered CDMO offering biologics and sterile fill-finish capabilities globally; comparable as a contract development and manufacturing partner for biologic drug substance and drug product.
• Samsung Biologics: Korean biologics CDMO operating one of the world's largest single-site mammalian cell culture capacities; directly comparable as an Asia-based commercial-scale biologics manufacturer competing for similar customers.
• Lonza Group: Swiss-headquartered global CDMO with large-scale mammalian cell biologics manufacturing including a Singapore footprint; directly comparable as a biologics contract manufacturer serving biopharma customers across Asia-Pacific.
• Thermo Fisher Scientific (Patheon/CDMO): Operates a global biologics and pharma services network through its Patheon business; comparable in scale and scope as a contract manufacturer for biopharmaceutical drug substance and finished products.
• WuXi Biologics: China-headquartered biologics CDMO with end-to-end development and manufacturing services, including Singapore and Asia-Pacific operations; directly comparable as an Asia-based biologics manufacturing partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amgen-singapore-manufacturing

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about amgen singapore manufacturing